Arimidex vs. Kanjinti

• Are Arimidex and Kanjinti the Same Thing?
• What Are Possible Side Effects of Arimidex?
• What Are Possible Side Effects of Kanjinti?
• What Is Arimidex?
• What Is Kanjinti?
• What Drugs Interact with Arimidex?
• What Drugs Interact with Kanjinti?
• How Should Arimidex Be Taken?
• How Should Kanjinti Be Taken?

Arimidex (anastrozole) and Kanjinti (trastuzumab-anns) are used to treat breast cancer.

Arimidex is used in postmenopausal women. Arimidex is often given to women whose cancer has progressed even after taking tamoxifen (Nolvadex, Soltamox).

Kanjinti is specifically indicated for the treatment of HER2 overexpressing breast cancer and it is also used for the treatment of HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

Arimidex and Kanjinti belong to different drug classes. Arimidex is a nonsteroidal aromatase inhibitor and Kanjinti is a HER2/neu receptor antagonist.

Side effects of Arimidex and Kanjinti that are similar include diarrhea, nausea, headache, cough, trouble sleeping (insomnia), and weight changes.

Side effects of Arimidex that are different from Kanjinti include constipation, vomiting, upset stomach, loss of appetite, body aches and pains (back pain, bone pain, joint pain or stiffness), breast swelling/tenderness/pain, dry mouth, scratchy or sore throat, dizziness, tiredness, weakness, flushing and sweating (hot flashes/hot flushes), vaginal bleeding, hair thinning, depression, mood changes, problems with your fingers while gripping, and numbness, tingling, cold feeling, or weakness in your hand or wrist.

Side effects of Kanjinti that are different from Arimidex include chills, fever, infection, congestive heart failure, rash, low white blood cell count (neutropenia), fatigue, anemia, inflammation of the mouth and lips, upper respiratory tract infections, low blood platelets (thrombocytopenia), mucosal inflammation, runny or stuffy nose, changes in taste.

Arimidex may interact with tamoxifen or an estrogen medication (such as hormone replacement therapy, estrogen creams, or birth control pills, injections, implants, skin patches, and vaginal rings).

Kanjinti may interact with anthracycline.

Common side effects of Arimidex include:

• stomach upset,
• nausea,
• vomiting,
• flushing (warmth, redness, or tingly feeling),
• constipation,
• headache,
• confusion,
• memory problems,
• loss of balance or coordination,
• blurred vision,
• double vision,
• eye redness,
• lightheadedness,
• dizziness,
• spinning sensation,
• drowsiness,
• sleep problems (insomnia),
• stuffy nose,
• itching, or
• rash, especially during the first few days as your body adjusts to this medication.

Tell your doctor if you experience serious side effects of Arimidex including:

• fever,
• chills,
• flu symptoms,
• slow heart rate,
• feeling like you might pass out,
• seizures (convulsions), or
• jaundice (yellowing of your skin or eyes).

Common side effects of Kanjinti include:

• headache,
• diarrhea,
• nausea,
• chills,
• fever,
• infection,
• congestive heart failure,
• insomnia,
• cough,
• rash,
• low white blood cell count (neutropenia),
• fatigue,
• anemia,
• inflammation of the mouth and lips,
• weight loss,
• upper respiratory tract infections,
• low blood platelets (thrombocytopenia),
• mucosal inflammation,
• runny or stuffy nose,
• changes in taste

Arimidex (anastrozole) is a non-steroidal aromatase inhibitor used to treat breast cancer in postmenopausal women. Arimidex is often given to women whose cancer has progressed even after taking tamoxifen (Nolvadex, Soltamox). Arimidex is available in generic form.

Kanjinti (trastuzumab-anns) is a HER2/neu receptor antagonist indicated for the treatment of HER2 overexpressing breast cancer and the treatment of HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

Arimidex may interact with tamoxifen or an estrogen medication (such as hormone replacement therapy, estrogen creams, or birth control pills, injections, implants, skin patches, and vaginal rings)..

Kanjinti may interact with anthracycline. Tell your doctor all medications and supplements you use. Kanjinti is not recommended for use during pregnancy; it may harm a fetus. Females of reproductive potential are advised to use effective contraception during treatment with Kanjinti and for 7 months following the last dose. It is unknown if Kanjinti passes into breast milk or how it would affect a nursing infant. Consult your doctor before breastfeeding.

The dose of Arimidex is one 1 mg tablet taken once a day. For patients with advanced breast cancer, the medication should be continued until tumor progression.

The dose and regimen of Kanjinti depends on the condition being treated.